Stephen Markham
Psychiatric/Mental Health · Adrian, MINPI 1790377331
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,721 of the $8,220 with a category attached, or 81.8%. 22 manufacturers reported payments, led by AbbVie at 30.2% of the total. 2025 is the largest year on record at $3,185, 3.4 times the $923 reported in 2022. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$876
- Otsuka America Pharmaceutical, Inc.$773
- Neurocrine Biosciences, Inc.$714
- Vanda Pharmaceuticals Inc.$671
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$1,30016%
- Food & beverage$6,72182%
- Education$1992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $2,484 |
| Teva Pharmaceuticals USA, Inc. | 46 | $1,011 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $876 |
| Otsuka America Pharmaceutical, Inc. | 36 | $773 |
| Neurocrine Biosciences, Inc. | 33 | $714 |
| Vanda Pharmaceuticals Inc. | 21 | $671 |
| Alkermes, Inc. | 18 | $340 |
| Lundbeck LLC | 14 | $299 |
| Corium, LLC | 18 | $293 |
| Axsome Therapeutics, Inc. | 17 | $249 |
| E.r. Squibb & Sons, L.L.C. | 16 | $199 |
| Novo Nordisk | 4 | $80 |
| Sage Therapeutics, LLC | 2 | $42 |
| Tris Pharma Inc | 2 | $33 |
| Johnson & Johnson | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| GSK | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,220 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $192,334 |
| VraylarCariprazine Hcl | 22 | $30,244 |
| RexultiBrexpiprazole | 17 | $23,471 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $15,354 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,453 |
| Aripiprazole | 29 | $5,121 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,989 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,369 |
| Fluvoxamine Maleate | 19 | $946 |
| Prazosin Hcl | 59 | $747 |
| Olanzapine | 68 | $672 |
| Quetiapine Fumarate | 46 | $555 |
| Duloxetine Hcl | 31 | $549 |
| Buspirone Hcl | 54 | $537 |
| Lamotrigine | 42 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,011 | $192,33418 claims |
| AbbVieVraylar | $2,484 | $30,24422 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $773 | $23,47117 claims |
| Axsome Therapeutics, Inc.Auvelity | $249 | $15,35420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $8,45318 claims |
| Lilly USA, LLCOlanzapine | $14 | $67268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Adrian
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.